Research Article
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
Table 2
Summary of the CD4 T cell responses to the Sp17 peptides by DLBCL patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DLBCL(dn): de novo diffuse large B cell lymphoma; DLBCL(t): diffuse large B cell lymphoma transformed; TCR: T cell rich B cell lymphoma. The results +/− are from triplicate ELISPOT cultures. The SD was calculated using standard techniques. Significant -IFN responses are highlighted in bold. ND, not determined. |